Novel Corona virus (COVID-19)
Corona contagions are positive sense single stranded RNA contagions that beget infection in nose, sinuses, or upper throat. It belongs to family of SARS and MERS. COVID-19 is the illness caused by SARS-COV-2, first outbreak does Wuhan megacity in China.
The pathogenesis of COVID-19 isn't defined but reports from numerous countries indicate that the contagion has the same medium by which it enters or invades host cells as SARS-COV. The origin of SARS-CoV-2 isn't well- established, still, it's established that batons are the fountainhead of affiliated contagions and that mortal to mortal transmission plays a critical part in its pathogenesis After entering into target cells following Shaft protein association with its receptor, viral RNA is reprised and polyadenylated, and encodes colorful structural andnon-structural polypeptide genes.
These polyproteins are adhered by proteases that parade chymotrypsin-suchlike exertion. Although transmembrane serine protease 2 (TMPRSS2) is the major protease associated with CoV activation and has been linked to SARS-CoV-2 activation, recent substantiation from single cell RNA-sequencing (scRNA-seq) analysis shows that ACE2 and TMPRSS2 aren't expressed in the same cell suggesting the involvement of other proteases similar as cathepsin B and L in this process.
In general, pattern recognition receptors (PRRs) fete overrunning pathogens including contagion’s. Contagions evoke several crucial host vulnerable responses similar as adding the release of seditious factors, induction and development of dendritic cells (DCs) and adding the conflation of type I interferons (IFNs), which are important in limiting viral spread. Both the ingrain and acquired vulnerable response is actuated by SARS-CoV-2. CD4 T cells stimulate B cells to produce contagion-specific antibodies including immunoglobulin (Ig) G and IgM and CD8 T cells directly kill contagion-infected cells. T coadjutor cells producer-inflammatory cytokines and intercessors to help the other vulnerable cells. SARS-CoV-2 can block the host vulnerable defense by suppressing T cell functions by converting their programmed cell deathe.g., by apoptosis. Likewise, the host product of complement factors similar as C3a and C5a and antibodies are critical in combating the viral infection.
Related Conference of Novel Corona virus (COVID-19)
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Novel Corona virus (COVID-19) Conference Speakers
Recommended Sessions
- Diagnostic Immunology
- Haematopoietic, Lymphoid Malignancies and Immune System Development
- Immune System and Immunology
- Immunization and Vaccination
- Veterinary Allergology
- Allergy and Immunology
- Autoimmune Diseases and HIV
- Immune Disorder
- Immune Response Regulation
- Immunogenetics
- Immunoresearch and Immunotechnology
- Microbial Parasitic and Fungal Immunology
- Mucosal and regional Immunology
- Neonatal and Pediatric Immunology
- NeuroImmunology
- Novel Corona virus (COVID-19)
- OncoImmunology
- Stem Cells Immunology
- Technological Innovations in Immunology
- Therapeutic approaches to autoimmunity
- Thyroid Autoimmunity
- Transplantation and Computational Immunology
- Vaccines and Immunotherapy
- Veterinary and Comparative Immunology
- Viral Immunology
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Cancer Immunology and Immunotherapy - European Immunology 2025 (Italy)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Diagnostic and Technological Novelty of Immunology - European Immunology 2025 (Italy)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Epidemiology - European Immunology 2025 (Italy)
- Immune System - European Immunology 2025 (Italy)
- Immunodeficiency - European Immunology 2025 (Italy)
- Immunogenetics - European Immunology 2025 (Italy)
- Immunoinformatics & Systems Immunology - European Immunology 2025 (Italy)
- Immunological Techniques - European Immunology 2025 (Italy)
- Immunology - European Immunology 2025 (Italy)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunotherapy - European Immunology 2025 (Italy)
- Immunotoxicology - European Immunology 2025 (Italy)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Neuroimmunology - European Immunology 2025 (Italy)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Parasite Immunology - European Immunology 2025 (Italy)
- Pediatrics Immunology - European Immunology 2025 (Italy)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Reproductive Immunology - European Immunology 2025 (Italy)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Transplantation Immunology - European Immunology 2025 (Italy)
- Viral Immunology - European Immunology 2025 (Italy)